R3 Stem Cell has been named Top 10 Biotech Startups 2021 by Life Sciences Review. This continues a plethora of Awards that R3 has received over the past years.
People ask us frequently how we can offer such high cell counts at pricing so low. We don’t sacrifice the quality of our biologics, we use our volume buying power to pass savings along to patients.”
SCOTTSDALE, ARIZONA, UNITED STATES, July 29, 2021 /EINPresswire.com/ — R3 Stem Cell was recently named to Top 10 Biotech Startups 2021 by Life Sciences Review. This continues a plethora of Awards that R3 has been receiving over the past few years including best USA Regenerative Therapy Company, Most Innovative, Fastest Growing and more.
Dr. David Greene, Founder and CEO of R3 Stem Cell, has been featured on the cover of Corporate Vision. R3 is the leader in global regenerative therapies.
Dr. David Greene, Founder and CEO of R3 Stem Cell, has been featured on the cover of Corporate Vision magazine for July 2021. Dr. Greene’s company is the leader in global regenerative therapies, with over 16,000 stem cell procedures performed worldwide in the past decade.
We have the best stem cell clinics providing very high cell counts and first rate care for extremely affordable pricing. It’s the most affordable stem cell therapy in the world!”
— CEO David Greene, MD, PhD, MBA
Dr. David Greene:
A Visionary Leader & Expert Professional Adamant at Improving Quality of Life with R3 Stem Cell
Established in 2012 and spearheaded by David Greene, R3 Stem Cell is delivering effective and safe regenerative therapies in the US & internationally. The company offers products and services internationally to both patients and providers. It has clinics that provide regenerative therapies, along with training workshops that teach providers about regenerative biologics and therapies. In addition, R3 now has sister companies offering products for distribution, practice marketing, and clinical trial research studies around the world.